IL111454A - קרבוקסאמידים הטרוציקליים מותמרים לשימוש כתכשירי רוקחות, מספר תרוכובת חדשות כאלו, והכנתן המדפיס הממשלתי מכשיר שרת, יומן הפטנטים, עמ' - Google Patents

קרבוקסאמידים הטרוציקליים מותמרים לשימוש כתכשירי רוקחות, מספר תרוכובת חדשות כאלו, והכנתן המדפיס הממשלתי מכשיר שרת, יומן הפטנטים, עמ'

Info

Publication number
IL111454A
IL111454A IL11145494A IL11145494A IL111454A IL 111454 A IL111454 A IL 111454A IL 11145494 A IL11145494 A IL 11145494A IL 11145494 A IL11145494 A IL 11145494A IL 111454 A IL111454 A IL 111454A
Authority
IL
Israel
Prior art keywords
alkyl
formula
radical
substituted
carboxylic acid
Prior art date
Application number
IL11145494A
Other languages
English (en)
Other versions
IL111454A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4337271A external-priority patent/DE4337271A1/de
Priority claimed from DE19944410881 external-priority patent/DE4410881A1/de
Priority claimed from DE19944433928 external-priority patent/DE4433928A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL111454A0 publication Critical patent/IL111454A0/xx
Publication of IL111454A publication Critical patent/IL111454A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL11145494A 1993-11-02 1994-10-30 קרבוקסאמידים הטרוציקליים מותמרים לשימוש כתכשירי רוקחות, מספר תרוכובת חדשות כאלו, והכנתן המדפיס הממשלתי מכשיר שרת, יומן הפטנטים, עמ' IL111454A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4337271A DE4337271A1 (de) 1993-11-02 1993-11-02 Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19944410881 DE4410881A1 (de) 1994-03-29 1994-03-29 Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19944433928 DE4433928A1 (de) 1994-09-23 1994-09-23 Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
IL111454A0 IL111454A0 (en) 1994-12-29
IL111454A true IL111454A (he) 2001-08-08

Family

ID=27205714

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11145494A IL111454A (he) 1993-11-02 1994-10-30 קרבוקסאמידים הטרוציקליים מותמרים לשימוש כתכשירי רוקחות, מספר תרוכובת חדשות כאלו, והכנתן המדפיס הממשלתי מכשיר שרת, יומן הפטנטים, עמ'

Country Status (20)

Country Link
EP (1) EP0650961B1 (he)
JP (1) JPH07228571A (he)
KR (1) KR950014072A (he)
CN (1) CN1107145A (he)
AT (1) ATE149486T1 (he)
AU (1) AU676775B2 (he)
CA (1) CA2134866A1 (he)
CY (1) CY2120B1 (he)
CZ (1) CZ289356B6 (he)
DE (1) DE59401924D1 (he)
DK (1) DK0650961T3 (he)
ES (1) ES2101421T3 (he)
GR (1) GR3023174T3 (he)
HK (1) HK1006711A1 (he)
IL (1) IL111454A (he)
MY (1) MY112413A (he)
NO (1) NO301880B1 (he)
NZ (1) NZ264821A (he)
PL (1) PL179794B1 (he)
TW (1) TW399046B (he)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (he) * 1995-09-28 2002-12-01 Hoechst Ag תרכובות ביניים להכנת אמידים מותמרים של קינולין - 2 - חומצה קרבוקסילית
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
JP4343681B2 (ja) 2001-05-08 2009-10-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト シアノアントラニルアミド誘導体およびそれらの薬剤としての使用
DE10123573B4 (de) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
DE10123587B4 (de) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
CN102526044A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
CN101664408B (zh) * 2001-12-06 2013-05-01 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1644336B1 (en) 2003-06-06 2011-01-19 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
ZA200806752B (en) 2006-01-27 2009-10-28 Fibrogen Inc Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
AU2007234408B2 (en) * 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
EP2044005B8 (en) 2006-06-26 2012-12-05 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
WO2009002533A1 (en) 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
EP2188252B1 (en) * 2007-09-20 2011-04-13 Amgen Inc. 1-(4-(4-benzylbenzamido)-benzyl)azetidine-3-carboxylic acid derivatives and related compounds as s1p receptor modulators for the treatment of immune disorders
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
KR101007674B1 (ko) * 2010-08-13 2011-01-13 김병두 보조 캡이 부착된 고속용사 건 및 코팅장치
KR101007675B1 (ko) * 2010-08-13 2011-01-13 김병두 보조 캡 이 부착된 플라즈마 용사 건 및 이를 활용하는 플라즈마 용사 시스템
NO2686520T3 (he) 2011-06-06 2018-03-17
NZ700760A (en) 2012-03-09 2016-08-26 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
PT2871180T (pt) 2012-07-04 2018-05-08 Agro Kanesho Co Ltd Derivado de éster do ácido 2-aminonicotínico e bactericida que o contém como ingrediente ativo
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
PT3470397T (pt) 2012-07-16 2022-02-18 Fibrogen Inc Formas cristalinas de um inibidor da prolil-hidroxilase
ES2694297T3 (es) 2013-01-24 2018-12-19 Fibrogen, Inc. Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
MA39033A1 (fr) 2013-11-15 2017-11-30 Akebia Therapeutics Inc Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
DK3277270T3 (da) 2015-04-01 2021-12-06 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CA3106385A1 (en) * 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
EP0541042A1 (de) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
BR9306058A (pt) * 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
NO301880B1 (no) 1997-12-22
KR950014072A (ko) 1995-06-15
PL179794B1 (pl) 2000-10-31
ATE149486T1 (de) 1997-03-15
NO944162L (no) 1995-05-03
EP0650961B1 (de) 1997-03-05
JPH07228571A (ja) 1995-08-29
HK1006711A1 (en) 1999-03-12
CZ289356B6 (cs) 2002-01-16
CY2120B1 (en) 2002-04-26
AU676775B2 (en) 1997-03-20
DE59401924D1 (de) 1997-04-10
TW399046B (en) 2000-07-21
AU7756494A (en) 1995-05-18
PL305646A1 (en) 1995-05-15
GR3023174T3 (en) 1997-07-30
CN1107145A (zh) 1995-08-23
NO944162D0 (no) 1994-11-01
CA2134866A1 (en) 1995-05-03
NZ264821A (en) 1997-02-24
ES2101421T3 (es) 1997-07-01
MY112413A (en) 2001-06-30
EP0650961A1 (de) 1995-05-03
CZ268394A3 (en) 1995-05-17
DK0650961T3 (da) 1997-09-15
IL111454A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
IL111454A (he) קרבוקסאמידים הטרוציקליים מותמרים לשימוש כתכשירי רוקחות, מספר תרוכובת חדשות כאלו, והכנתן המדפיס הממשלתי מכשיר שרת, יומן הפטנטים, עמ'
US5658933A (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
US5620995A (en) Substituted heterocyclic carboxyamides, their preparation and their use as pharmaceuticals
US5719164A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
US5792779A (en) Pyridinone thrombin inhibitors
RU2129545C1 (ru) Амиды сульфамидо- и сульфамидокарбонилпиридин-2-карбоновых кислот, способы их получения и фармацевтическая композиция
US5620996A (en) Sulfonamidocarbonyl pyridine-2-carboxesteramides and their pyridine-N-oxide compounds and their use as pharmaceuticals
CA2245811A1 (en) Pyridinone thrombin inhibitors
CA2145476A1 (en) Sulfonamidocarbonylpyridine-2-carboxamides and their pyridine-n-oxides, process for their preparation, and their use as pharmaceuticals
KR890001146B1 (ko) 아미도-아미노산 및 그의 제조 방법
CA2145473A1 (en) Substituted heterocyclic carboxamidoesters their preparation and their use as pharmaceuticals
FI90767C (fi) Menetelmä terapeuttisesti aktiivisten pyridiini-2,4- ja -2,5-dikarboksyylihappojohdannaisten valmistamiseksi
US5428046A (en) Acylsulfonamido- and sulfonamidopyridine-2-carboxylic acid esters and their pyridine N-oxides, processes for their preparation and their use as medicaments
DE4433928A1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE4434288A1 (de) Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE4410881A1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE4337270A1 (de) Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2145472A1 (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4337271A1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees